N/A N=27 Effects of Exercise Training on Pelvic Floor Symptoms and Function in Adults With Constipation
Constipation
Primary: Severity of Constipation Symptoms — 0.96; 0.97; 0.63; 0.67 score on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=40 The Effect of CSP01 on Chronic Idiopathic Constipation and Irritable Bowel Syndrome With Constipation
Constipation · Chronic Idiopathic Constipation · Irritable Bowel Syndrome With Constipation
Primary: Change From Baseline in Colonic Transit Time (CTT) — -727; -15; 366 minutes
Phase 3 N=40 Lubiprostone and Mucus Secretion in Patients With Chronic Constipation
Constipation
Primary: Change of Mucus and Mucin Secretion in Patients With Chronic Constipation and in Controls. — 260; 133; 229; 161 mg/hour
Phase 4 N=25 Effects of Lubiprostone on Small Bowel and Colonic Bacteria: A Correlation Study With Segmental and Whole Gut Transit
Constipation
Primary: Presence of Small Intestinal Bacterial Overgrowth — 8; 9 Participants — p=0.75
Phase 3 N=224 B. Lactis HN019 for Functional Constipation
Constipation
Primary: Whole Gut Transit Time
N/A N=12 Proof of Concept: "Bottom's Up" Seat to Treat Constipation
Constipation Aggravated · Pelvic Floor; Incompetency
Primary: Adverse Events — 0 Participants
Phase 1 N=41 Effect of Lubiprostone on Methanogenesis and Bowel Function in Chronic Constipation.
Chronic Constipation, Methanogenesis
Primary: Change in Methane Production — 10645; 14635 parts per million*minutes
N/A N=16 Effect of Kiwifruit on Gastrointestinal Fluid Distribution and Transit in Healthy Volunteers
Constipation · Diet Modification
Primary: Relaxation Time in Ascending Colon — 312; 256 seconds*minutes
Phase 4 N=60 Lubiprostone, Colonic Motility and Sensation
Healthy
Primary: Colonic Compliance — 16.60; 16.50 mm Hg
Phase 2 N=36 Effect of Ileal Bile Acid Transporter Inhibitor in Functional Constipation
Functional Constipation
Primary: Colonic Transit at 24 Hours — 2.68; 3.12; 1.93 units on a scale — p=0.059
Phase 4 N=18 Pregabalin on Colonic Motor and Sensory Function in Constipation Predominant Irritable Bowel Syndrome
Irritable Bowel Syndrome
Primary: Colonic Compliance — 18.96; 16.86; 15.99; 15.75 mm Hg
Phase 2 N=154 Post-Operative Constipation Following Total Knee Arthroplasty
Constipation
Primary: Bowel Movement (BM) Within 3 Days of Surgery — 29; 32 Participants — p=0.41
N/A N=50 The Efficacy of PX0612 In The Treatment Of Irritable Bowel Syndrome
Irritable Bowel Syndrome With Diarrhea
Primary: Change in the Bowel Movements (Stool Frequency) Between the 'Intervention' Group and the 'Placebo' Group Over the Study Period. — .46; .21 bowel movements/day
Phase 3 N=675 Efficacy and Safety of Acupuncture for Functional Constipation
Constipation
Primary: Change of the SBMs From Baseline at Week 4 — 2.7; 2.7; 2.2; 2.4 times per week — p=0.352
Phase 4 N=13 Study to Investigate Prucalopride vs. Polyethylene Glycol 3350 on Colon Activity
Chronic Constipation
Primary: The Number of High-Amplitude Propagating Contractions (HAPC) — 8.7; 2.9 Number of HAPC with amplitude ≥100mmHg — p=0.012
Phase 4 N=153 The Effect of Probiotics on Constipation, and Intestinal Microflora in Children With Functional Constipation
Functional Constipation
Primary: Change of Clostridium Butyricum Miyairi Expression After Probiotics Supplementation in Constipated Children. — 0.00486; 0.0000148; 0.00000189 number of bacteria per mg…
Phase 2 N=192 Dose-ranging Efficacy of Polydextrose Supplement on Colonic Transit Time and Symptoms in Adults With Functional Constipation
Functional Constipation
Primary: Change in Colonic Transit Time From Baseline to Day 15 — -1.7; 4.0; 2.5; 2.6 Hours
N/A N=102 Maintenance Treatment for Children With Constipation
Constipation
Primary: Treatment Recovery — 33; 19 participants — p=0.024
Phase 4 N=19 Effects of Lubiprostone on Gastric Function in Patients With Chronic Idiopathic Constipation
Chronic Idiopathic Constipation
Primary: Gastric Emptying — 0.27; 0.384; 0.04; 0.051 percent meal retention — p=0.003
Phase 4 N=54 Amitiza in Constipation Associated With PD (Parkinson's Disease)
Parkinson's Disease
Primary: Change From Baseline to End of Study — 64; 18.5 Percentage of participants
N/A N=52 Effects of Lubiprostone on Gastrointestinal Transit & pH in Irritable Bowel Syndrome (IBS) With Constipation
Irritable Bowel Syndrome · Constipation
Primary: Change in Gastric Emptying Time, Small Bowel Transit Time, Colon Transit Time and Whole Gut Transit Time From Baseline — 5.49; 6.52; -0.16; 0.2 hours
N/A N=84 Effect of Preoperative Fiber on Postoperative Bowel Function
Constipation · Prolapse, Vaginal
Primary: Time to First Bowel Movement After Surgery — 66.5; 68.3 hours
Phase 3 N=643 Trial of Linaclotide in Patients With Chronic Constipation
Chronic Constipation
Primary: Complete Spontaneous Bowel Movement (CSBM) Overall Responder — 46; 42; 7 participants — p=<0.0001
Phase 3 N=487 Safety and Efficacy of Linaclotide in Patients With Chronic Constipation and Prominent Abdominal Bloating
Chronic Constipation · Constipation
Primary: 9/12 Week Complete Spontaneous Bowel Movement (CSBM) 3+1 Responder — 13; 24; 158; 129 participants — p=0.0264
Phase 2 N=30 Use of Pyridostigmine for Constipation in Diabetics
Constipation · Diabetes Mellitus · Colonic Transit
Primary: Colonic Geometric Center at 24 Hours (GC24) Measured by Scintigraphy — 1.96; 1.98; 2.45; 1.84 units on a scale — p=<0.01
Phase 2 N=131 Evaluation of the Efficacy and Safety of ADL5945 for the Treatment of Opioid-induced Constipation in Adults Taking Opioid Therapy for Chronic Noncancer Pain
Opioid Induced Constipation
Primary: Change From Baseline in the Weekly Average of Spontaneous Bowel Movements (SBMs) During Treatment — 1.96; 3.42; 1.44 Number of SBMs/week
Phase 2 N=36 Cheno Effect on Transit in Health and IBS-C
Constipation-predominant Irritable Bowel Syndrome
Primary: Colonic Geometric Center at 24 Hours (GC24) — 3.1; 3.5; 2.2 units on a scale
Phase 4 N=76 The Effectiveness of Lubiprostone in Constipated Diabetics
Constipation · Diabetes
Primary: Efficacy, Measured by the Average Number of Spontaneous Bowel Movements (SBMs) Per Week — 4.85; 1.40; 3.81; 2.41 spontaneous bowel movements
Phase 2 N=97 A Dose Determination Study of Chinese Herbal Medicine for Functional Constipation
Constipation
Primary: Responder for Complete Spontaneous Bowel Movement (CSBM) — 10; 14; 17; 22 participants — p=<0.05
Phase 2 N=120 An Effectiveness and Safety Study of Chinese Herbal Medicine for Functional Constipation
Functional Gastrointestinal Disorders · Constipation
Primary: Responder of Complete Spontaneous Bowel Movement (CSBM) — 26; 5; 34; 55 participants — p=<0.05